Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials Meeting Abstract
| Authors: | Martin, M.; Loibl, S.; Hyslop, T.; de la Haba-Rodriguez, J.; Aktas, B.; Cirrincione, C.; Carrasco, E. M.; Mehta, K.; Barry, W. T.; Morales, S.; Carey, L. A.; Garcia Saenz, J. A.; Partridge, A.; Martinez, N.; Hahn, O. M.; Winer, E. P.; Guerrero, A.; Hudis, C.; Casas, M.; Dickler, M. N. |
| Abstract Title: | Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 35s |
| Language: | English |
| ACCESSION: | WOS:000411895701149 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.1012 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1012 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
